Inventor
William C. Patt
Inventor
Chelsea, MI, US
Overview
Patents· 43 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds32%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
A61KPreparations for medical, dental or toiletry purposes13%
C07HSugars10%
C07CAcyclic or carbocyclic compounds8%
C07KPeptides7%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
C40BCombinatorial chemistry2%
C07BGeneral methods of organic chemistry1%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
PatentTitleYear
9,382,228'N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities'20169,309,224'N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities'20169,187,474'Raf inhibitor compounds'20159,133,183'Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities'20158,188,113'Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases'20127,897,762'Kinase inhibitors useful for the treatment of proliferative diseases'20117,829,737'Protein tyrosine phosphatase inhibitors and methods of use thereof'20107,504,389'Protein tyrosine phosphatase inhibitors and methods of use thereof'20097,214,712'Isophthalic acid derivatives as matrix metalloproteinase inhibitors'20077,205,295'Benzoxazin-3-ones and derivatives thereof as therapeutic agents'20077,015,237'Pyridine matrix metalloproteinase inhibitors'20066,995,151'Isophthalic acid derivatives as matrix metalloproteinase inhibitors'20066,936,616'Pyrimidine matrix metalloproteinase inhibitors'20056,906,094'1,2,4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase'20056,881,743'Pyridine matrix metalloproteinase inhibitors'20056,686,355'Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors'20046,559,142'Sulfonamide matrix metalloproteinase inhibitors'20036,297,274'Nonpeptide endothelin antagonists with increased water solubility'20016,133,263'Endothelin antagonists with ether-linked groups'20006,043,241'Ketoacid endothelin antagonists'20006,017,918'Phenyl glycine compounds and methods of treating atherosclerosis and restenosis'20006,017,951'Butenolide endothelin antagonists'20006,017,916'Nonpeptide endothelin antagonists I'20005,998,468'Furanone endothelin antagonists'19995,922,759'Butenolide endothelin antagonists'19995,891,892'Small molecule biaryl compounds as inhibitors of endothelin converting enzyme'19995,691,373'Nonpeptide endothelin antagonists I'19975,643,879'Amino-substituted heterocycles as renin inhibitors'19975,453,488'Amino-substituted heterocycles as renin inhibitors'19955,260,278'Diol-containing renin inhibitors'19935,238,923'Amino-substituted heterocycles as renin inhibitors'19935,219,851'Tetrahydroisoquinoline-type renin inhibiting peptides'19935,135,914'Substituted derivatives of 3-amino-2-hydroxypropionic acid as inhibitors of renin'19925,036,053'Diol-containing renin inhibitors'19914,868,160'Method of treating psychosis using N.sup.6 -substituted -5\'-oxidized adenosine analogs'19894,791,103'2,N.sup.6 -disubstituted adenosines, derivatives and methods of use'19884,764,506'N.sup.6 -(benzothien-3-yl)ethyl adenosine; N.sup.6 -(benzothien-3-yl)ethyl adenosine, S-oxide; and N.sup.6 -(benzothien-3-yl)ethyl S,S-dioxide adenosine'19884,738,954'Novel N.sup.6 -substituted-5\'-oxidized adenosine analogs'19884,673,670'N.sup.6 -acenaphthyl adenosines and analogs thereof'19874,636,493'Benzothien-3-yl adenosine; benzothien-3-yl adenosine, S-oxide; and benzothien-3-yl, S,S-dioxide adenosine compounds'19874,616,003'N.sup.6 -dihydroxypropyladenosines'19864,614,732'N.sup.6 -acenaphthyl adenosines and analogs thereof'19864,600,707'Benzothien-3-yl adenosine; benzothien-3-yl adenosine, S-oxide; and benzothien-3-yl, S,S-dioxide adenosine compounds'1986Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1986–2007Patents assigned to WARNER LAMBERT CO (35)· patent assignee history
1986–2007Based in Chelsea, MI, US· patent location history
1988–1989Based in Feasterville, PA, US· patent location history
2009–2010Patents assigned to CEPTYR INC (2)· patent assignee history
2009–2016Based in Lawrence, KS, US· patent location history
2011–2016Patents assigned to DECIPHERA PHARMACEUTICALS LLC (5)· patent assignee history
2012Patents assigned to DECIPHERA PHARMACEUTICALS INC (1)· patent assignee history
2012Patents assigned to FLYNN DANIEL L (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| WARNER LAMBERT CO | 35 | 1986–2007 |
| DECIPHERA PHARMACEUTICALS LLC | 5 | 2011–2016 |
| CEPTYR INC | 2 | 2009–2010 |
| DECIPHERA PHARMACEUTICALS INC | 1 | 2012 |
| FLYNN DANIEL L | 1 | 2012 |
Locations
| Location | Patents | Span |
|---|---|---|
| Chelsea, MI, US | 33 | 1986–2007 |
| Lawrence, KS, US | 8 | 2009–2016 |
| Feasterville, Pennsylvania, US | 2 | 1988–1989 |